Amyotrophic Lateral Sclerosis Treatment Market is Expected to Expand at an Impressive Rate by 2026 – Eurowire

Posted: Published on November 5th, 2020

This post was added by Alex Diaz-Granados

Amyotrophic lateral sclerosis (ALS) is a neurological disease and also termed as Lou Gehrigs disease. The disease affects the motor neurons, which control the action of voluntary muscles, as a result the messages between brain and muscle fibers are blocked. ALS could occur in a person due to genetic inheritance, mutation in gene which encodes enzyme copper-zinc superoxide dismutase coupled with defect in chromosome 9. This disease is more prevalent in males. All these abnormalities results in the release of glutamate which damage the motor neurons controlling voluntary muscles. ALS projects various symptoms such as spasticity, cramps, fasciculation, respiratory problems and muscles weakness. The mortality rate has been studied to be higher in the ALS patients mainly due to respiratory failures. ALS results in the inability to breathe; this is due to non- functioning of diaphragram and chest muscles caused due to muscle weakness It has been estimated that every year around 5,000 people in U.S. are diagnosed with amyotrophic lateral sclerosis.

Request a PDF Brochure https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1514

Amyotrophic lateral sclerosis is diagnosed with electromyography (EMG) test which detect electrical activities of muscles. In addition, ALS can also be diagnosed through nerve conduction study (NCS) test. This test measures electrical energy used to send a signal by neurons. The ALS detection only by symptoms is difficult since various other diseases such as spinal cord tumor, syringomelia, cervical spondylosis and herniated neck disc. Succeeding diagnosis, physicians prescribe various treatment options such as physical, speech, occupational, chemotherapy and other therapies. Chemotherapy includes only one drug which is riluzole and is the only drug approved by FDA. Riluzole reduces motor neuron damage by decreasing the release of glutamate. Other treatments which can be given to an ALS patient include muscle relaxants, ventilators and drugs which would reduce fatigue, excessive salivation and control spasticity. These drugs would only improve the quality of life of ALS patient.

Request for Analysis of COVID19 Impact on Amyotrophic Lateral Sclerosis Treatment Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1514

The age groups of 55 to 66 are highly prone to ALS due to weak immune system. Rise in aging population worldwide would augment the growth of this market. In addition, the government is also concerned for the various treatment options of ALS. Recently in 2008, Collaborative ALS Drug Discovery Initiative (CADDI) helped to initiate and accelerate the new drug development and effective treatment of ALS. This initiative increased the number of ALS treating pipeline drugs. Despite all these, various factors such as high cost of treatment, unawareness about the disease and availability of ineffective diagnosis methods would hinder the growth of this market.

Pre-Book Amyotrophic Lateral Sclerosis Treatment Market Report https://www.transparencymarketresearch.com/checkout.php?rep_id=1514&ltype=S

Some of the major market players in amyotrophic lateral sclerosis market include Mitsubishi Tanabe Pharma, Avicena Inc., Sanofi Inc., Biogen Inc. and others.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact Us

Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY 12207 United States USA Canada Toll Free: 866-552-3453 Website:https://www.transparencymarketresearch.com

Read More Reports: https://www.prnewswire.co.uk/news-releases/technological-advances-in-magnetic-resonance-imaging-to-help-in-better-management-of-neurological-diseases-market-to-clock-cagr-of-5-2-during-2018-2026-tmr-883512245.html

See more here:
Amyotrophic Lateral Sclerosis Treatment Market is Expected to Expand at an Impressive Rate by 2026 - Eurowire

Related Posts
This entry was posted in ALS Treatment. Bookmark the permalink.

Comments are closed.